Skip to main content
Premium Trial:

Request an Annual Quote

DermTech: DermTech PLAplus

DermTech has launched its PLAplus test, which adds telomerase reverse transcriptase promoter DNA driver mutation analyses to the firm's current RNA gene expression based Pigmented Lesion Assay (PLA) for early melanoma detection. The firm said the add-on improves the combined tests' sensitivity from 91 percent to 97 percent.